Security Investigation

Inari Medical, Inc. (NasdaqGS: NARI)

49 Days left to seek lead plaintiff status.

Company Name:Inari Medical, Inc.
Stock Symbol:NasdaqGS: NARI
Court:Southern District of New York
Class Period Start:02/24/2022
Class Period End (inclusive):02/28/2024
Filing Deadline:07/12/2024

Contact a Lawyer Now

(877) 515-1850

Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until July 12, 2024 to file lead plaintiff applications in a securities class action lawsuit against Inari Medical, Inc. (NasdaqGS: NARI).

Inari Medical and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws. 

On February 29, 2024, the Company disclosed the receipt of a civil investigative demand from the U.S. Department of Justice in connection with an investigation under the federal Anti-Kickback Statute and Civil False Claims Act, requesting information and documents primarily relating to meals and consulting service payments provided to health care professionals, and warned that “depending on the outcome of the investigation, there may be a material impact on our business, results of operations, or financial condition.”.  

On this news, the price of Inari Medical’s shares fell by over $12 per share, or 21%, from a closing price of $58.26 per share on February 28, 2024 to $46.12 per share on February 29, 2024 – wiping out approximately $700 million in market capitalization in one trading day.

If you purchased shares of Inari Medical and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at at 1-877-515-1850 or via email (lewis.kahn@ksfcounsel.com), or fill out the form on this page.

The case is Michiana Area Electrical Workers’ Pension Fund, IBEW Local 153 v. Inari Medical, Inc., et al, No. 24-cv-03686.

Click here to read the first filed complaint.